FDA Approves Zanubrutinib for Waldenström’s Macroglobulinemia
This novel, small molecule inhibitor of Bruton's tyrosine kinase, was investigated in ASPEN study that compared zanubrutinib and ibrutinib in patients with MYD88 L265P mutation
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
This novel, small molecule inhibitor of Bruton's tyrosine kinase, was investigated in ASPEN study that compared zanubrutinib and ibrutinib in patients with MYD88 L265P mutation
New prediction model can provide probability of survival and leukaemia transformation at diagnosis of myelodysplastic syndrome and throughout a patient's disease course
Data from patients with confirmed syndrome registered in the International Replication Repair Deficiency Consortium
The results of the GROINSS-V-II study
It also approved the Oncomine Dx Target Test as a companion diagnostic device to aid in patient selection
Findings from an assessment of the utility of broad germline panel testing in a prospective pan-cancer cohort
When aided by a deep learning model, pathologists make faster and more accurate diagnoses of soft tissue sarcomas
Findings from a post hoc KEYNOTE-061 study analysis in second-line treatment for gastric/gastro-oesophageal junction adenocarcinoma
Evidence for efficacy in the adjuvant treatment of patients with high-risk urothelial carcinoma is based on the results of CHECKMATE-274 study
The results from a phase I study with tumour-infiltrating lymphocytes infusion in patients with metastatic non-small cell lung cancer
It also approved the VENTANA MMR RxDx Panel as a companion diagnostic device to select patients
Findings from a phase III study of hippocampal avoidance during prophylactic cranial irradiation in patients with small-cell lung cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.